Characteristics and Glycemic Outcomes of T2D Patients (Pts) Titrated to 60 U/day with Insulin Glargine/Lixisenatide Fixed-Ratio Combination (iGlarLixi) vs. Insulin in the LixiLan-L Trial

被引：0
|
作者：
Blonde, Lawrence
Bailey, Timothy S.
Chao, Jason
Dex, Terry
Frias, Juan P.
Meneghini, Luigi F.
Roberts, Michelle
Aroda, Vanita R.
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1107-P
引用
收藏
页码：A294 / A294
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial
    Rosenstock, Julio
    Diamant, Michaela
    Aroda, Vanita R.
    Silvestre, Louise
    Souhami, Elisabeth
    Zhou, Tianyue
    Perfetti, Riccardo
    Fonseca, Vivian
    DIABETES CARE, 2016, 39 (09) : 1579 - 1586
  • [32] Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes
    Rosenstock, Julio
    Handelsman, Yehuda
    Vidal, Josep
    Blasco, F. Javier Ampudia
    Giorgino, Francesco
    Liu, Minzhi
    Perfetti, Riccardo
    Meier, Juris J.
    DIABETES OBESITY & METABOLISM, 2018, 20 (12): : 2821 - 2829
  • [33] Benefits of a Fixed-Ratio Formulation of Once-Daily Insulin Glargine/Lixisenatide (LixiLan) vs. Glargine in Type 2 Diabetes (T2DM) Inadequately Controlled on Metformin
    Rosenstock, Julio
    Diamant, Michaela
    Silvestre, Louise
    Souhami, Elisabeth
    Zhou, Tianyue
    Fonseca, Vivian
    DIABETES, 2014, 63 : A87 - A88
  • [34] Clinical impact of LixiLan, a fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on oral agents: LixiLan-O trial
    Rosenstock, J.
    Aronson, R.
    Hanefeld, M.
    Piatti, P.
    Serusclat, P.
    Cheng, X.
    Zhou, T.
    Niemoeller, E.
    Souhami, E.
    Grunberger, G.
    Davies, M.
    DIABETOLOGIA, 2016, 59 : S384 - S385
  • [35] Efficacy of Insulin Glargine/Lixisenatide Fixed-Ratio Combination in Patients with T2D According to Health Care Effectiveness Data and Information Set (HEDIS) Measures
    Sugimoto, Danny H.
    Dex, Terry
    Stager, William
    Yu, Christine
    Aroda, Vanita R.
    DIABETES, 2016, 65 : A250 - A250
  • [36] Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L
    Blonde, Lawrence
    Berard, Lori
    Saremi, Aramesh
    Huang, Yao
    Aroda, Vanita R.
    Raccah, Denis
    DIABETES THERAPY, 2020, 11 (04) : 1007 - 1015
  • [37] Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L
    Lawrence Blonde
    Lori Berard
    Aramesh Saremi
    Yao Huang
    Vanita R. Aroda
    Denis Raccah
    Diabetes Therapy, 2020, 11 : 1007 - 1015
  • [38] Clinical Impact of Titratable Fixed-Ratio Combination of Insulin Glargine/Lixisenatide vs. Each Component Alone in Type 2 Diabetes Inadequately Controlled on Oral Agents: LixiLan-O Trial
    Rosenstock, Julio
    Aronson, Ronnie
    Hanefeld, Markolf
    Piatti, Piermarco
    Serusclat, Pierre
    Cheng, Xi
    Zhou, Tianyue
    Nie-Moeller, Elisabeth
    Souhami, Elisabeth
    Grunberger, George
    Davies, Melanie
    DIABETES, 2016, 65 : A48 - A49
  • [39] Efficacy of iGlarLixi, a fixed-ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements
    Sugimoto, Danny H.
    Dex, Terry
    Stager, William
    Aroda, Vanita R.
    DIABETES OBESITY & METABOLISM, 2018, 20 (11): : 2680 - 2684
  • [40] Efficacy and safety of iGlarLixi vs insulin glargine 100 U/ml in Chinese people with type 2 diabetes (T2D) inadequately controlled on basal insulin (BI): LixiLan-L-China trial
    Guo, X.
    Zhang, J.
    Dong, X.
    Lu, Y.
    Pang, W.
    Gu, S.
    Ping, L.
    Nian, G.
    Niemoeller, E.
    Souhami, E.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 270 - 270
12345